Moderna and BioNTech’s stocks hit new lows as investor disappointment with crashing revenues grows.
BioNTech’s sales fell 95% YoY last quarter, while Moderna’s revenues declined 93% YoY in Q2. Both companies have forecasted significantly lower Covid vaccine sales for this year.